A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Monthly Rate of HAE Attacks for Each Lanadelumab-treated Participant During the Lanadelumab Exposure Period

Time frame · From the first dose of study drug up to approximately 3 years 8 months

The HAE monthly attack rate is defined as the total number of attacks that occurred when the participant was in a lanadelumab exposure period, divided by the total lanadelumab exposure time (in days), multiplied by 28 days.

Median Time to Complete Attack Resolution for Icatibant Treated Participants

Time frame · From the first dose of study drug up to approximately 3 years 8 months

Time to complete attack resolution among icatibant-treated participants during the retrospective observation period is defined as the time between icatibant first injection and the earliest time of complete resolution of symptoms for each attack during the retrospective observation period that was treated with icatibant.

Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) During Lanadelumab and Icatibant Exposure Period

Time frame · From the first dose of study drug up to approximately 3 years 8 months

An AE is any untoward medical occurrence in a participant administered a studied drug and which does not necessarily have to have a causal relationship with the studied drug. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, a new disease or worsening in severity or frequency of a concomitant disease, temporally associated with the use of a studied drug, whether or not the event is considered causally related to the use of the product. An SAE is any untoward medical occurrence that at any dose: results in death, life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent, significant disability/incapacity, a congenital abnormality/birth defect, an important medical event in the opinion of the healthcare provider, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.

Dosage of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period

Time frame · From the first dose of study drug up to approximately 3 years 8 months

Dosage of lanadelumab used during the lanadelumab exposure period will be assessed.

Frequency Administration of Lanadelumab Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period

Time frame · From the first dose of study drug up to approximately 3 years 8 months

Frequency administration of lanadelumab among lanadelumab-treated participant during the lanadelumab exposure period will be assessed.

Number of Participants with Reasons of Discontinuation of Lanadelumab During the Lanadelumab Exposure Period

Time frame · From the first dose of study drug up to approximately 3 years 8 months

Number of participants with reasons of discontinuation of lanadelumab during the lanadelumab exposure period will be assessed.

Time to Lanadelumab Discontinuation Among Lanadelumab-treated Participant During the Lanadelumab Exposure Period

Time frame · From the first dose of study drug up to approximately 3 years 8 months

The time to lanadelumab discontinuation is defined as the time from lanadelumab initiation to the first lanadelumab discontinuation.